{"filing":{"accession_number":"0001104659-26-068591","cik":"0001640266","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"tm2616041d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm"},"events":[{"id":7703,"run_id":6767,"accession_number":"0001104659-26-068591","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Voyager announced FDA clearance of its IND application for VY1706, a tau-targeting gene therapy for Alzheimer's disease, with plans to initiate a clinical trial in H2 2026. This is a material regulatory milestone for a clinical-stage biotech company, but does not fit neatly into the predefined taxonomy—it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or going concern. The IND clearance represents significant progress in the company's pipeline and would affect a reasonable investor's assessment of the registrant's prospects.","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3003,"accession_number":"0001104659-26-068591","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Voyager announced FDA clearance of its IND application for VY1706, a tau-targeting gene therapy for Alzheimer's disease, with plans to initiate a clinical trial in H2 2026. This is a material regulatory milestone for a clinical-stage biotech company, but does not fit neatly into the predefined taxonomy—it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or going concern. The IND clearance represents significant progress in the company's pipeline and would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:14:34.569417+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3003,"accession_number":"0001104659-26-068591","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Voyager announced FDA clearance of its IND application for VY1706, a tau-targeting gene therapy for Alzheimer's disease, with plans to initiate a clinical trial in H2 2026. This is a material regulatory milestone for a clinical-stage biotech company, but does not fit neatly into the predefined taxonomy—it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or going concern. The IND clearance represents significant progress in the company's pipeline and would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:14:34.569417+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-06-01"}]}